| Autor: |
de Sousa LG; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu S; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhosale P; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Altan M; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Darbonne W; Roche/Genentech, South San Francisco, CA, USA., Schulze K; Roche/Genentech, South San Francisco, CA, USA., Dervin S; Roche/Genentech, South San Francisco, CA, USA., Yun C; Roche/Genentech, South San Francisco, CA, USA., Mahvash A; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Verma A; Department of Pathology, Yale-New Haven Hospital, New Haven, CT, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gite S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cuentas EP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cho WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba I; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Woodman SE; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Halperin DM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: dmhalperin@mdanderson.org., Ferrarotto R; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rferrarotto@mdanderson.org. |
| Abstrakt: |
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: R. Ferrarotto: Paid consultant/advisory board member for Elevar Therapeutics, Prelude Therapeutics, Regeneron, Sanofi, Eisai, and Remix. Royalties from UpToDate. Supported by research funding to MD Anderson Cancer Center from Ayala, Merck, Genentech, Pfizer, Nanobiotix, EMD Serono, Viracta, Seagen, and ISA Therapeutics. M. Altan: Supported by research funding to MD Anderson Cancer Center from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab, and Gilead. Member of the advisory board for GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca, and Insightec. Speaker fees from AstraZeneca, Nektar Therapeutics, and Society for Immunotherapy of Cancer. Participation in the safety review committee for the Nanobiotix–MD Anderson alliance Hengenix. C. Yun: shareholder of Genentech/Roche. All other authors: none. |
Full Text from ScienceDirect